Recent events
Recent events tied to this brand in public sources.
Back to profile30 entries · Page 2 of 2
2020
BeiGene and Amgen's global oncology partnership takes effect
BeiGene announced that its global oncology strategic partnership with Amgen, agreed on October 31, 2019, had received shareholder approval, met other closing conditions, and become effective.
2020
Amgen completes purchase of BeiGene equity stake
Amgen completed its purchase of an approximately 20.5% equity stake in BeiGene for approximately $2.8 billion in cash.
2019
FDA approves Amgen's AVSOLA
The U.S. Food and Drug Administration approved Amgen's AVSOLA for all approved indications of the reference product Remicade.
2019
Amgen licenses JSP191 worldwide rights to Jasper Therapeutics
As part of Jasper Therapeutics' Series A financing, Amgen licensed worldwide rights to JSP191 to Jasper, including translational science and materials from Stanford University.
2019
Amgen completes acquisition of worldwide rights to Otezla
Amgen announced that it completed its acquisition of worldwide rights to Otezla from Celgene Corporation. The acquisition was completed for $13.4 billion in cash, or approximately $11.2 billion net of anticipated future cash tax benefits.
2019
Amgen raises 2019 profit and revenue forecasts
Amgen raised its full-year 2019 profit and revenue forecasts; it now expected adjusted earnings per share of $14.50–$14.70 and revenue of $23.1–$23.3 billion.
2019
Amgen and BeiGene agree to co-develop oncology medicines globally
Under their announced collaboration, Amgen and BeiGene agreed to co-develop 20 Amgen oncology pipeline medicines globally and share development costs. BeiGene also agreed to commercialize three Amgen products in China under the cooperation agreement.
2019
Amgen announces purchase of a 20.5% stake in BeiGene
Amgen announced that it would purchase a 20.5% stake in BeiGene for approximately $2.7 billion in cash. The transaction had board approval and was expected to close in the first quarter of 2020, subject to stated conditions.
2019
Amgen agrees to acquire a 20.5% stake in BeiGene
As part of the announced transaction, Amgen agreed to purchase 20.5% of BeiGene's shares for approximately $2.7 billion in cash or at $174.85 per American depositary share.
2019
Amgen reports third-quarter 2019 financial results
Amgen reported third-quarter 2019 financial results, including total revenues of $5.7 billion and GAAP earnings per share of $3.27.